A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Afimetoran, an Oral, Once-Daily Equipotent TLR 7/8 Inhibitor, in Participants with Active Systemic Lupus Erythematosus (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB23; Pres time: Nov 11, 2026; 09:00 AM - 09:15 AM; Location: Chapin Theater; In Person; No abstract available
Clinical • Late-breaking abstract • P2 data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
|
|
Kenneth Kalunian, MD, FACR
|